54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

Key Takeaways Explain This Topic AI

Serum 25-hydroxyvitamin D [25(OH)D] is the definitive circulating biomarker of total body stores (deficient <20 ng/mL [<50 nmol/L], insufficient 20-29 ng/mL, sufficient >=30 ng/mL); 1,25-dihydroxyvitamin D [1,25(OH)2D] should NOT be ordered to evaluate vitamin D status, as secondary hyperparathyroidism upregulates renal 1-alpha-hydroxylase, maintaining normal or paradoxically elevated 1,25(OH)2D levels despite severe tissue deficiency.

Severe vitamin D deficiency causes secondary hyperparathyroidism, hypophosphatemia, and osteomalacia in adults (characterized by impaired mineralization of osteoid matrix, diffuse bone pain, proximal muscle weakness, elevated alkaline phosphatase, and pathognomonic Looser zones / pseudofractures on radiographs); treatment requires high-dose ergocalciferol (D2) 50,000 IU orally once weekly for 8 weeks, followed by maintenance cholecalciferol (D3) 1,000 to 2,000 IU daily.

Vitamin B12 (cobalamin) deficiency causes macrocytic megaloblastic anemia (MCV >100 fL, hypersegmented neutrophils) and Subacute Combined Degeneration of the spinal cord (demyelination of dorsal columns and lateral corticospinal tracts); borderline B12 levels (200-350 pg/mL) require reflex testing for methylmalonic acid (MMA) and homocysteine: BOTH elevated confirms B12 deficiency, whereas elevated homocysteine with normal MMA indicates folate deficiency.

Empiric administration of folic acid alone in an undiagnosed patient with vitamin B12 deficiency will correct the megaloblastic anemia while masking and permitting irreversible progression of disabling subacute combined spinal cord degeneration; always confirm normal B12 levels before or concurrently when treating folate deficiency.

Iron deficiency anemia is the most common micronutrient deficiency worldwide; a serum ferritin <30-45 ng/mL is the most sensitive and specific diagnostic biomarker, though ferritin is an acute-phase reactant that may be falsely normal in chronic inflammatory conditions (where ferritin <100 ng/mL or transferrin saturation <20% suggests deficiency); unexplained iron deficiency in adult men or postmenopausal women mandates bidirectional endoscopy (colonoscopy and EGD) to exclude gastrointestinal malignancy.

Last updated: September 2026

Vitamin D Deficiency & Metabolic Bone Pathophysiology

Vitamin D is a seco-steroid prohormone essential for calcium and phosphorus homeostasis, skeletal mineralization, and neuromuscular function. It exists in two primary forms: vitamin D3 (cholecalciferol) , synthesized endogenously in the epidermis upon exposure to solar ultraviolet B (UVB, 290–315 nm) radiation from 7-dehydrocholesterol or ingested from animal dietary sources (oily fish, egg yolks), and vitamin D2 (ergocalciferol) , derived from fungal and plant irradiation of ergosterol.

Metabolism & Circulating Biomarkers

Hepatic 25-Hydroxylation : Both cholecalciferol and ergocalciferol are transported to the liver bound to vitamin D-binding protein (DBP), where the microsomal enzyme 25-hydroxylase (CYP2R1) converts them into 25-hydroxyvitamin D [25(OH)D, calcidiol] .

The Clinical Gold Standard : Serum 25(OH)D is the only reliable biomarker reflecting total body vitamin D nutritional status. It has a circulating biological half-life of 2 to 3 weeks and is not tightly regulated by parathyroid hormone (PTH).

Renal 1-Alpha-Hydroxylation : In the proximal convoluted tubules of the kidney, the mitochondrial enzyme 1-alpha-hydroxylase (CYP27B1) converts 25(OH)D into the biologically active hormonal form, 1,25-dihydroxyvitamin D [1,25(OH)2D, calcitriol] .

Calcitriol has a short half-life of 4 to 6 hours and circulates at concentrations 1,000-fold lower than calcidiol.

Renal CYP27B1 is tightly stimulated by PTH and hypophosphatemia, and inhibited by fibroblast growth factor 23 (FGF23) and hypercalcemia. THE VITAMIN D METABOLIC CASCADE

Solar UVB Radiation (290-315 nm) Dietary Intake
│ │
▼ ▼
Epidermal 7-Dehydrocholesterol ──► Vitamin D3 / D2 (Cholecalciferol / Ergocalciferol)
│
▼ [Liver: 25-Hydroxylase (CYP2R1)]
25-Hydroxyvitamin D [25(OH)D]
BEST BIOMARKER OF TOTAL BODY STORES
Half-life: 2–3 weeks
│
▼ [Kidney: 1α-Hydroxylase (CYP27B1)]
│ ▲ Stimulated by High PTH, Low Phos
│ ▼ Inhibited by FGF23, High Ca
▼
1,25-Dihydroxyvitamin D [1,25(OH)₂D, Calcitriol]
Biologically active hormone
Promotes intestinal Ca²⁺ and PO₄³⁻ absorption

Warning

THE COMMON LABORATORY PITFALL: ORDERING 1,25(OH)2D INSTEAD OF 25(OH)D Ordering 1,25-dihydroxyvitamin D to assess vitamin D status is a serious clinical mistake. In patients with severe nutritional vitamin D deficiency, low calcium absorption triggers compensatory secondary hyperparathyroidism . High circulating PTH strongly stimulates renal 1-alpha-hydroxylase, maintaining 1,25(OH)2D levels within the normal reference range or driving them paradoxically high , even when the patient's skeletal stores are completely depleted. Always order serum 25-hydroxyvitamin D [25(OH)D] .

Laboratory Classification of Vitamin D Status (Endocrine Society)
Deficiency : Serum 25(OH)D <20 ng/mL (<50 nmol/L)
Insufficiency : Serum 25(OH)D 20 to 29 ng/mL (50 to 74 nmol/L)
Sufficiency : Serum 25(OH)D ≥30 ng/mL (≥75 nmol/L) (optimal range: 30 to 50 ng/mL)

Toxicity : Serum 25(OH)D >100 to 150 ng/mL (>250 to 375 nmol/L) (manifests with hypercalcemia, hypercalciuria, acute kidney injury, and soft tissue calcification)

Clinical Consequences: Osteomalacia & Rickets

When serum 25(OH)D drops below 20 ng/mL, intestinal calcium absorption falls from ~30-40% down to 10-15%. The resulting hypocalcemia stimulates parathyroid chief cells to secrete PTH ( secondary hyperparathyroidism ). PTH induces renal calcium retention, promotes renal phosphate wasting (hypophosphatemia), and increases osteoclastic bone resorption:

Osteomalacia (Adults) :

Characterized by defective and delayed mineralization of newly synthesized organic bone matrix ( osteoid ).

Clinical features: Insidious, diffuse, dull aching bone pain (especially in the pelvis, spine, ribs, and lower extremities); proximal muscle weakness (causing a waddling, antalgic gait and difficulty rising from a chair or climbing stairs); bone tenderness upon firm palpation of the anterior tibia and sternum.

Laboratory profile: Low or low-normal serum calcium , low serum phosphate , elevated serum intact PTH , elevated bone-specific alkaline phosphatase (BSAP) , and markedly low 25(OH)D.

Radiographic features: Generalized osteopenia, cortical thinning, and pathognomonic Looser zones (pseudofractures / Milkman lines) —narrow, transverse, radiolucent bands perpendicular to the cortex, typically bilateral and symmetric, located along the medial femoral neck, pubic rami, ribs, and lateral axillary border of the scapulae.

Rickets (Children) :

Occurs prior to the fusion of epiphyseal growth plates. Defective chondrocyte apoptosis and impaired mineralization of cartilage matrix lead to growth plate widening and deformities: craniotabes (soft, thinning skull bones), rachitic rosary (enlargement of costochondral junctions), Harrison groove (diaphragmatic pull indentation of lower ribs), and progressive bowing of the weight-bearing long bones ( genu varum or genu valgum ).

Pharmacologic Treatment of Severe Deficiency

High-Dose Loading Protocol (for 25(OH)D <20 ng/mL):

Ergocalciferol (Vitamin D2) 50,000 IU orally once weekly for 8 weeks (or Cholecalciferol [Vitamin D3] 50,000 IU weekly x 8 weeks).

Alternatively: 6,000 IU of daily vitamin D3 for 8 weeks.

Maintenance Therapy :

Following the 8-week loading regimen, transition to maintenance therapy with Cholecalciferol (Vitamin D3) 1,000 to 2,000 IU orally daily (or 50,000 IU every 2 to 4 weeks).

Repeat serum 25(OH)D measurement at 3 months to confirm achievement of sufficiency (target ≥30 ng/mL).

High-Risk Populations Requiring Higher Maintenance Doses (3,000–6,000 IU/day) :

Patients with obesity (BMI ≥30 kg/m²: vitamin D is fat-soluble and sequestered within excess subcutaneous adipose tissue, reducing circulating bioavailability).

Malabsorptive disorders (celiac disease, Crohn's disease, post-bariatric surgery [RYGB]).

Patients taking hepatic cytochrome P450-inducing anticonvulsants (phenytoin, carbamazepine, phenobarbital) or rifampin, which dramatically accelerate the metabolic catabolism of 25(OH)D and 1,25(OH)2D into inactive calcitroic acid.

Vitamin B12 (Cobalamin) Deficiency: Hematologic & Neurologic Manifestations

Vitamin B12 is an essential water-soluble organometallic compound synthesized exclusively by microorganisms. Dietary sources are limited strictly to animal products (meat, poultry, fish, shellfish, eggs, and dairy products) and fortified foods.

Physiology of Absorption & Etiological Drivers

Gastric Phase : Ingested B12 is bound to dietary proteins. In the stomach, gastric acid and pepsin cleave B12 from proteins. B12 immediately binds to salivary haptocorrin (R-factor) , which protects it from acid degradation.

Pancreatic & Duodenal Phase : In the duodenum, pancreatic proteases degrade haptocorrin, releasing free cobalamin. Free cobalamin then binds to intrinsic factor (IF) , a 45-kDa glycoprotein secreted by gastric parietal cells .

Ileal Phase : The stable B12-IF complex transits through the jejunum into the terminal ileum , where it binds to specific cubilin-amnionless receptors on enterocyte brush borders and is absorbed via calcium-dependent endocytosis. ETIOLOGICAL SPECTRUM OF VITAMIN B12 DEFICIENCY

Etiological Category Specific Mechanism Clinical Context

═════════════════════════════════════════════════════════════════════════════════════════════════════════════════

Pernicious Anemia Autoimmune destruction of gastric parietal cells ──► Middle-aged/older adults; coexists
Complete loss of Intrinsic Factor and HCl with Hashimoto's, vitiligo, T1D

Strict Vegan Diet Zero intake of animal products; total body stores Onset delayed 3-5 years due to
(2-5 mg stored in liver) gradually deplete efficient enterohepatic recycling

Surgical Anatomical • Roux-en-Y Gastric Bypass (loss of IF & acid) Mandates lifelong prophylactic
Modifications • Terminal Ileal Resection (>20-30 cm resected) oral or parenteral cobalamin

Gastrointestinal Disease • Ileal Crohn's disease (mucosal inflammation) Malabsorption of intact
Celiac sprue; Small Intestinal Bacterial Overgrowth B12-IF complex; bacterial consumption

Drug-Induced • Metformin: Interferes with Ca²⁺-dependent ileal Occurs in 10-30% of chronic users;
Cobalamin Malabsorption binding of B12-IF complex monitor levels every 1-2 years
PPIs / H2-Blockers: Hypochlorhydria impairs Cleavage of food-bound cobalamin
peptic cleavage from dietary protein impaired (free B12 absorbed normally)

Clinical Manifestations

Hematologic Features (Megaloblastic Anemia) :

Macrocytic anemia with an MCV typically >100 fL (frequently >110–120 fL).

Peripheral blood smear: Hypersegmented neutrophils (defined as the presence of ≥1 six-lobed neutrophil or ≥5% five-lobed neutrophils), anisocytosis, poikilocytosis, and oval macrocytes.

Severe deficiency results in ineffective erythropoiesis and intramedullary hemolysis: severe pancytopenia (leukopenia, thrombocytopenia), elevated indirect bilirubin, elevated lactate dehydrogenase (LDH, often marked), and low reticulocyte production index.

Neurologic Manifestations: Subacute Combined Degeneration (SCD) :

Cobalamin is an essential cofactor for methionine synthase , which converts homocysteine to methionine (vital for S-adenosylmethionine [SAM] synthesis, the methyl donor for myelin sheath maintenance), and methylmalonyl-CoA mutase , which converts methylmalonyl-CoA to succinyl-CoA. Impaired mutase activity results in accumulation of methylmalonic acid and abnormal odd-chain fatty acids that incorporate into and destabilize neural membranes.

Dorsal (Posterior) Columns Demyelination : Produces loss of vibration sensation and proprioception in lower extremities, sensory ataxia (wide-based, unsteady, slapping gait), positive Romberg sign, and Lhermitte-like electrical sensations.

Lateral Corticospinal Tracts Demyelination : Produces upper motor neuron signs: lower extremity spasticity, hyperreflexia, clonus, and positive extensor plantar responses ( Babinski sign ).

Peripheral Sensorimotor Neuropathy : Symmetric distal sensory paresthesias ("stocking-glove" numbness, tingling, burning).

Neuropsychiatric Features ("Megaloblastic Madness") : Progressive memory loss, irritability, depression, paranoia, hallucinations, and reversible cognitive decline / dementia.

Caution

THE FOLIC ACID TRAP (NEUROLOGICAL DISASTER) Folic acid (vitamin B9) supplementation bypasses the B12-dependent methionine synthase block in the thymidylate synthesis pathway, completely restoring DNA replication in hematopoietic precursors and curing the megaloblastic anemia . However, folic acid does NOT correct the impaired myelin sheath maintenance or methylmalonyl-CoA mutase dysfunction. Consequently, administering high-dose folic acid to a patient with unrecognized B12 deficiency masks the anemia while allowing irreversible spinal cord demyelination (Subacute Combined Degeneration) and permanent paraplegia to progress unimpeded . Always measure serum B12 prior to or concurrently with folate supplementation!

Diagnostic Evaluation & Reflex Testing

Serum Vitamin B12 Level :

<200 pg/mL (<148 pmol/L) : Definitively diagnostic of deficiency.

200 to 350 pg/mL : Borderline / equivocal zone. Up to 30% of patients with tissue-level B12 deficiency have serum levels in this intermediate range.

>350 pg/mL : Deficiency is highly unlikely.

Metabolic Biomarkers: Methylmalonic Acid (MMA) & Total Homocysteine :

Indicated whenever serum B12 is borderline (200–350 pg/mL) or when high clinical suspicion exists despite normal serum levels.

Elevated Serum MMA (>0.40 umol/L) AND Elevated Homocysteine (>15 umol/L) : Definitively confirms Vitamin B12 Deficiency (sensitivity >98%).

Normal MMA AND Elevated Homocysteine : Diagnostic of Folate (Vitamin B9) Deficiency .

Note : Serum MMA can be falsely elevated in chronic kidney disease due to reduced renal excretion.

Pernicious Anemia Autoantibodies :

Anti-Intrinsic Factor (anti-IF) Antibodies : Extraordinarily high specificity (>95%), moderate sensitivity (~50–70%). A positive test establishes pernicious anemia.

Anti-Parietal Cell Antibodies : High sensitivity (~90%), but low specificity (~50%; found in atrophic gastritis and autoimmune thyroiditis). DIAGNOSTIC ALGORITHM: B12 VS. FOLATE DEFICIENCY

Borderline Serum B12 (200-350 pg/mL)
│
▼
Order Serum MMA and Homocysteine
│
┌─────────────────────────┴─────────────────────────┐
▼ ▼
BOTH MMA & Homocysteine Homocysteine ELEVATED
ELEVATED MMA NORMAL
│ │
▼ ▼
VITAMIN B12 DEFICIENCY FOLATE DEFICIENCY
│ │
Order Anti-Intrinsic Factor Prescribe Oral
Antibodies Folic Acid 1 mg Daily
Pharmacotherapy & Route of Administration

Intramuscular Cyanocobalamin : Traditional regimen for severe hematologic manifestations, neurologic symptoms, or malabsorptive states:

1,000 mcg IM daily for 7 days , followed by
1,000 mcg IM once weekly for 4 weeks , then

1,000 mcg IM once monthly for life (or transition to high-dose oral).

High-Dose Oral Cyanocobalamin (1,000 to 2,000 mcg PO daily) :

Multiple randomized controlled trials demonstrate that high-dose oral cobalamin is equally effective to intramuscular injections for normalizing hematologic indices and resolving neurologic deficits, even in patients with pernicious anemia or bariatric surgery.

Physiological Basis : Approximately 1% to 2% of an oral dose of free crystalline cobalamin is absorbed via passive, non-carrier-mediated diffusion across the entire mucosal surface of the gastrointestinal tract, completely independent of intrinsic factor or terminal ileal receptors. A daily oral dose of 1,000 to 2,000 mcg delivers 10 to 20 mcg of absorbed B12, far exceeding the daily physiological requirement (2.4 mcg/day).

Iron Deficiency Anemia (IDA): Biomarkers, Endoscopy & Dosing Protocols

Iron deficiency is the single most common nutritional deficiency worldwide, affecting over 1.5 billion people. In primary care, iron deficiency anemia (IDA) is rarely a primary disease itself; rather, it is a clinical manifestation of an underlying pathological bleeding site or malabsorptive disorder that demands systematic investigation.

Iron Kinetics & Biomarker Interpretation LABORATORY PROFILES: IRON DEFICIENCY VS. ANEMIA OF CHRONIC DISEASE

Biomarker Normal Range Iron Deficiency Anemia Anemia of Chronic Disease (ACD)

Serum Ferritin 30 – 300 ng/mL < 30 ng/mL Normal to Elevated (>100 ng/mL)
(Most sensitive & specific) (Acute-phase reactant; hepcidin-driven)

Transferrin Saturation (TSAT) 20% – 50% < 15% – 20% Normal or Low (10% – 20%)
(Serum Iron / TIBC x 100)

Serum Iron 60 – 170 ug/dL Low (< 40 ug/dL) Low (< 50 ug/dL)

Total Iron-Binding Capacity 240 – 450 ug/dL Elevated (> 450 ug/dL) Low or Normal (< 250 ug/dL)
(TIBC) (Liver upregulates transferrin)

Soluble Transferrin Receptor 1.2 – 3.0 mg/L ELEVATED NORMAL
(sTfR)

Important

SERUM FERRITIN IN THE PRESENCE OF SYSTEMIC INFLAMMATION Serum ferritin is an intracellular iron storage protein and a potent acute-phase reactant upregulated by circulating inflammatory cytokines (IL-6, IL-1, TNF-α). In healthy individuals, a ferritin <30 to 45 ng/mL is virtually 100% specific for iron deficiency . However, in patients with chronic inflammatory states (e.g., chronic kidney disease, rheumatoid arthritis, active inflammatory bowel disease, congestive heart failure, malignancy, or acute infections), ferritin can be falsely elevated into the normal range (50 to 100+ ng/mL). In such patients, an iron deficiency state is diagnosed if serum ferritin is <100 ng/mL OR if transferrin saturation (TSAT) is <20% .

Clinical Etiologies & Mandatory Endoscopic Workup

Premenopausal Females : Menorrhagia and pregnancy are the leading causes. However, gastrointestinal pathology must still be considered if anemia is severe or refractory.

Adult Men & Postmenopausal Females :

Dietary iron deficiency in an adult consuming a Western diet is practically non-existent.

The Golden Rule : Iron deficiency anemia in an adult male or postmenopausal female is presumed to be caused by occult gastrointestinal bleeding until proven otherwise .

Mandatory Diagnostic Standard : Bidirectional endoscopy—comprising both Colonoscopy (to rule out right-sided colon cancer, polyps, vascular ectasias) AND Esophagogastroduodenoscopy (EGD) with duodenal biopsies (to rule out gastric adenocarcinoma, peptic ulcer disease, Cameron lesions in hiatal hernias, and celiac disease )—is indicated, regardless of whether fecal occult blood tests are positive or negative.

Oral Iron Therapy: The Paradigm Shift to Alternate-Day Dosing

The Biology of Hepcidin : Ingestion of an oral iron bolus stimulates hepatic synthesis and secretion of hepcidin , the master systemic regulator of iron metabolism. Hepcidin binds to and internalizes ferroportin , the sole cellular iron exporter on duodenal enterocytes and reticuloendothelial macrophages. Following an oral iron dose, hepcidin levels spike for 24 to 48 hours , blocking subsequent iron absorption from successive doses and trapping unabsorbed iron in the intestinal lumen, causing severe gastrointestinal toxicity (nausea, constipation, epigastric cramps, dark tarry stools).

Alternate-Day Dosing Protocol :

Prescribe ferrous sulfate 325 mg (containing 65 mg of elemental iron) once every other day (e.g., Monday, Wednesday, Friday, Sunday mornings).

Landmark randomized trials have demonstrated that alternate-day dosing yields equal or superior total fractional iron absorption compared to daily or three-times-daily dosing, with a significantly lower incidence of gastrointestinal adverse effects and markedly superior patient adherence.

Administration Instructions : Take on an empty stomach with a source of ascorbic acid ( vitamin C 250 to 500 mg or orange juice), which maintains iron in its soluble ferrous ( Fe 2 + \text{Fe}^{2+} Fe 2 + ) state. Avoid co-ingestion with calcium supplements, antacids, dairy products, coffee, or tea (tannins and polyphenols bind iron, forming insoluble non-absorbable chelates).

Indications for Intravenous Iron Pharmacotherapy

Modern intravenous iron formulations (e.g., ferric carboxymaltose, ferric derisomaltose, ferumoxytol, iron sucrose ) have an outstanding safety profile with negligible risk of anaphylaxis (unlike historical high-molecular-weight iron dextran):

Intolerance or failure of oral iron (severe gastrointestinal side effects despite alternate-day dosing or failure to raise hemoglobin by ≥1.0 g/dL after 4 weeks).

Severe malabsorptive states (post-Roux-en-Y gastric bypass, active celiac sprue, short bowel syndrome).

Active Inflammatory Bowel Disease (Crohn's disease, Ulcerative Colitis) : Unabsorbed luminal oral iron exacerbates mucosal inflammation, ulceration, and dysbiosis; IV iron bypasses the gut.

Chronic Kidney Disease (Stages 3–5D) : Especially patients receiving erythropoiesis-stimulating agents (ESAs).

Heart Failure with Reduced Ejection Fraction (HFrEF, NYHA Class II–III) : The FAIR-HF and CONFIRM-HF trials proved that IV iron improves functional capacity, exercise performance, and reduces HF hospitalizations in patients with ferritin <100 ng/mL (or ferritin 100–299 ng/mL with TSAT <20%), even in the absence of anemia.

Second or Third Trimester Pregnancy with severe anemia (Hb <10.0 g/dL) or oral iron intolerance, where rapid repletion is essential prior to delivery.

Pediatric & Geriatric Malnutrition Syndromes
Pediatric Malnutrition: Failure to Thrive (FTT)

Failure to thrive is a state of undernutrition characterized by inadequate weight gain or physical growth over time in infants and young children:

Diagnostic Anthropometric Criteria :

Weight-for-age falling below the 3rd or 5th percentile on standardized WHO (age <2 years) or CDC (age ≥2 years) growth charts.

Weight-for-length falling below the 3rd or 5th percentile .

Deceleration of growth velocity across two or more major percentile lines (e.g., falling from the 50th to below the 10th percentile) over a 3- to 6-month period.

Etiological Classification :

Inadequate Caloric Intake (Most Common, >80% of cases) : Incorrect infant formula preparation (excessive water dilution due to financial poverty or misunderstanding), feeding aversion, severe oral motor dysfunction, neglect, breastfeeding failure, parent-child interaction difficulties.

Inadequate Nutrient Absorption : Celiac disease, cystic fibrosis (exocrine pancreatic insufficiency), cow's milk protein enteropathy, short bowel syndrome.

Increased Energy Expenditure : Congenital heart disease, chronic pulmonary disease (bronchopulmonary dysplasia, cystic fibrosis), chronic infections (HIV, recurrent UTIs), hyperthyroidism.

Primary Care Management : Comprehensive dietary recall (3-day food diary), observing a feeding encounter, high-calorie nutritional supplementation (fortifying formula to 24–30 kcal/oz), and interdisciplinary collaboration (social work, lactation consulting, speech pathology for swallow mechanics).

Geriatric Malnutrition & The Mini Nutritional Assessment (MNA)

Protein-energy malnutrition in older adults is strongly associated with sarcopenia, immune dysfunction, impaired wound healing, functional decline, and heightened mortality.

Diagnostic Warning Flags :

Unintentional weight loss of ≥5% of body weight in 1 month , or ≥10% in 6 months .

Serum albumin <3.0 g/dL or prealbumin <10 mg/dL (reflects disease acuity and inflammation rather than pure nutritional status).

The Mini Nutritional Assessment (MNA) :

A validated 18-item clinical tool designed specifically for geriatric populations. The short-form MNA (MNA-SF) scores food intake decline, weight loss, mobility, acute disease/psychological stress, neuropsychological problems (dementia/depression), and BMI (or calf circumference):

12 to 14 points : Normal nutritional status.

8 to 11 points : At risk of malnutrition.

0 to 7 points : Malnourished.

Primary Care Interventions :

Identification and treatment of reversible drivers: depression, poorly fitting dentures, xerostomia, polypharmacy causing anorexia (e.g., digoxin, anticholinergics, SSRIs), dysphagia, food insecurity, and isolation.

Nutritional prescription: High-protein, nutrient-dense oral nutritional supplements (ONS) between meals; liberalization of overly restrictive chronic disease diets (e.g., loosening strict low-salt or diabetic diets that impair palatability).